Tumor-associated antigen-derived peptide-Major Histocompatibility Complex class II complex (TAA-pMHC-II)

Tumor-associated antigen-derived peptide-Major Histocompatibility Complex class II (TAA-pMHC-II) complexes are specialized molecular assemblies presented on the surface of professional antigen-presenting cells, particularly dendritic cells (Source: Roche & Furuta, 2015, Nature Reviews Immunology). These complexes are formed when dendritic cells internalize tumor proteins, degrade them into peptide fragments, and load these fragments onto MHC class II molecules (HLA-DR, HLA-DQ, or HLA-DP) for transport to the cell surface (Source: Axelrod et al., 2019, JCI Insight). The primary biological role of these complexes is to serve as a ligand for the T-cell receptors (TCRs) of CD4+ T helper cells, which are essential for initiating and sustaining a comprehensive anti-tumor immune response (Source: Alspach et al., 2019, Nature). By activating CD4+ T cells, these complexes facilitate the maturation of high-affinity B cells and the optimal priming of CD8+ cytotoxic T cells, while also potentially mediating direct anti-tumor effects through cytokine secretion (Source: Tay et al., 2021, Frontiers in Immunology). In the context of oncology, the density and diversity of TAA-pMHC-II complexes on dendritic cells are often insufficient to overcome tumor-induced immunosuppression, or the tumor may downregulate MHC expression to evade detection (Source: Garrido et al., 2016, Cancer Immunology, Immunotherapy). Therapeutic strategies such as dendritic cell vaccines (e.g., Sipuleucel-T) and peptide-based vaccines aim to artificially increase the presentation of these complexes to stimulate a potent immune attack against the malignancy (Source: Kantoff et al., 2010, NEJM). Furthermore, emerging therapies like TCR-like antibodies and TCR-engineered T cells are being designed to specifically recognize the unique structural interface of the peptide and the MHC molecule, offering a highly targeted approach to cancer immunotherapy (Source: He et al., 2019, Journal of Hematology & Oncology).

Other names

TAA-MHC II complexpMHCIITumor antigen-MHC class II complexMHC class II-restricted tumor antigenTumor-associated antigen-derived peptide-MHC class II complexes on dendritic cells

Activation of CD4+ T-helper cells via TCR binding to the peptide-MHC interface, leading to cytokine secretion and enhancement of the adaptive anti-tumor immune response (Source: Alspach et al., 2019, Nature).